Literature DB >> 20486326

Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system.

Carlos Iribarren1, Irina V Tolstykh, Mary K Miller, Mark D Eisner.   

Abstract

BACKGROUND: The association between asthma and anaphylaxis remains poorly understood.
OBJECTIVE: To ascertain, in a managed care organization in northern California, the association of asthma and asthma severity with future risk of anaphylactic shock and other selected allergy diagnoses.
METHODS: Using electronic data and validated algorithms, we assembled a cohort of 526,406 patients who met the criteria for asthma between 1996 and 2006 and a referent cohort (with no utilization for asthma) individually matched on age, sex, and race/ethnicity. In each cohort, 54% of patients were female and 55% were white; their mean (SD) age was 24 (20) years. The main outcome measures were anaphylactic shock (caused by an adverse food reaction, caused by serum, or other/idiopathic), allergic urticaria, anaphylaxis after sting(s), and angioedema.
RESULTS: The incidence of anaphylactic shock was 109.0 per 100,000 person-years in the asthma cohort and 19.9 per 100,000 person-years in the referent cohort. After adjustment for age, sex, race/ethnicity, comorbidities, and immunotherapy, asthma was associated with a 5.2-fold (95% confidence interval, 4.7- to 5.6-fold) increased hazard of anaphylactic shock. Asthma was also significantly associated with an increased risk of the 3 selected allergy diagnoses, with hazard ratios of 1.4 to 1.9. A significant trend by severity of asthma was apparent for food-related and other/idiopathic anaphylactic shock and for anaphylaxis after sting(s).
CONCLUSIONS: In this insured population, asthma was prospectively associated with increased risk of anaphylactic shock and other allergy diagnoses. However, the effect of asthma severity was not consistent across outcome measures.

Entities:  

Mesh:

Year:  2010        PMID: 20486326     DOI: 10.1016/j.anai.2010.03.004

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  16 in total

1.  Food-induced anaphylaxis.

Authors:  Antonella Cianferoni; Antonella Muraro
Journal:  Immunol Allergy Clin North Am       Date:  2011-11-21       Impact factor: 3.479

Review 2.  [Epidemiology of anaphylaxis].

Authors:  M Worm
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

3.  Development and validation of an algorithm to identify drug-induced anaphylaxis in the Beijing Pharmacovigilance Database.

Authors:  Ying Zhao; Haidong Lu; Sydney Thai; Xiaotong Li; John Hui; Huilin Tang; Suodi Zhai; Lulu Sun; Tiansheng Wang
Journal:  Int J Clin Pharm       Date:  2018-02-20

Review 4.  Food allergies and asthma.

Authors:  Julie Wang; Andrew H Liu
Journal:  Curr Opin Allergy Clin Immunol       Date:  2011-06

5.  Risk of anaphylaxis after vaccination in children and adults.

Authors:  Michael M McNeil; Eric S Weintraub; Jonathan Duffy; Lakshmi Sukumaran; Steven J Jacobsen; Nicola P Klein; Simon J Hambidge; Grace M Lee; Lisa A Jackson; Stephanie A Irving; Jennifer P King; Elyse O Kharbanda; Robert A Bednarczyk; Frank DeStefano
Journal:  J Allergy Clin Immunol       Date:  2015-10-06       Impact factor: 10.793

6.  Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel.

Authors:  Kathleen E Walsh; Sarah L Cutrona; Sarah Foy; Meghan A Baker; Susan Forrow; Azadeh Shoaibi; Pamala A Pawloski; Michelle Conroy; Andrew M Fine; Lise E Nigrovic; Nandini Selvam; Mano S Selvan; William O Cooper; Susan Andrade
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-09-05       Impact factor: 2.890

7.  Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis.

Authors:  Dana L Baker; Gerald R Nakamura; Henry B Lowman; Saloumeh Kadkhodayan Fischer
Journal:  AAPS J       Date:  2015-09-04       Impact factor: 4.009

8.  World allergy organization guidelines for the assessment and management of anaphylaxis.

Authors:  F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal:  World Allergy Organ J       Date:  2011-02-23       Impact factor: 4.084

9.  Concomitant chronic pulmonary diseases and their association with hospital outcomes in patients with anaphylaxis and other allergic conditions: a cohort study.

Authors:  Zuber D Mulla; F Estelle R Simons
Journal:  BMJ Open       Date:  2013-07-31       Impact factor: 2.692

10.  Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.

Authors:  Lisha Li; Zixi Wang; Le Cui; Yingyang Xu; Kai Guan; Bin Zhao
Journal:  Clin Transl Allergy       Date:  2021-06-03       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.